Human papillomavirus-positive oropharyngeal squamous cell carcinoma, a cancer of the tonsils and base of tongue that has become the dominant form of head and neck cancer in many Western countries, generally carries a favorable prognosis compared with its HPV-negative counterpart. Even so, between 10 and 25 percent of patients experience progressive disease within three years of treatment, making reliable surveillance a central concern for clinicians. The standard follow-up regimen typically involves contrast-enhanced CT of the neck and chest or PET/CT scanning, interpreted using the Neck Imaging Reporting and Data System, known as NI-RADS, a structured risk classification designed to standardize how radiologists flag suspicious findings. Yet imaging after surgery is complicated by anatomical distortion, scar tissue, and inflammation, all of which can mimic or obscure tumor recurrence.

The UNC team, led by Makayla R. Matthews of the School of Medicine together with colleagues in otolaryngology, radiology, and radiation oncology, reviewed the records of patients treated with definitive surgical resection between 2020 and 2023. All patients underwent standard post-treatment imaging, and ctHPVDNA samples were also collected and independently assessed. The cohort was characteristic of the modern HPV-positive throat cancer epidemic: 81 percent of the patients were male, the median age was 58, and a majority had never smoked. Most tumors arose in the tonsil, followed by the base of tongue, and nearly all patients presented with lymph node involvement, ranging from N1 to N3 disease under the seventh edition of the American Joint Committee on Cancer staging system.

During follow-up, four of the sixteen patients, or 25 percent of the cohort, developed biopsy-proven recurrence, with half of those events occurring at locoregional sites and half at distant locations. The median time to detectable recurrence was 14 months, though the range was wide, spanning from 3 to 42 months after treatment. This recurrence burden aligns with the upper end of what has been reported for HPV-positive oropharyngeal cancer populations and underscores why surveillance strategies matter: catching a returning tumor early, while it is still small and localized, can open the door to potentially curative salvage therapy.

The performance gap between the two surveillance modalities was the study’s most consequential finding. When radiologists applied NI-RADS criteria to post-treatment imaging, they flagged four suspected locoregional recurrences. Only one of these proved to be a true positive on biopsy; the other three were false positives. That translates to a sensitivity of 50 percent, a specificity of 75 percent, a positive predictive value of just 25 percent, and a negative predictive value of 90 percent for imaging-based detection. In practical terms, imaging missed as many recurrences as it caught, and three-quarters of the positive imaging findings did not correspond to actual cancer.

The ctHPVDNA assay told a different story. The blood test correctly identified two locoregional recurrence events and two distant recurrence events, all four of which were confirmed by biopsy, and it produced no false positives. That yields 100 percent sensitivity, 100 percent specificity, 100 percent positive predictive value, and 100 percent negative predictive value within this small cohort. The assay works on a principle analogous to liquid biopsies developed for other cancers: tumors driven by HPV shed fragments of viral DNA that carry tumor-tissue-modified signatures into the circulation, where they can be quantified using digital PCR. Because the viral signal originates from malignant cells rather than normal tissue, a positive result carries strong biological specificity for active disease.

The technical logic of the test helps explain its precision. HPV-positive tumor cells release short fragments of viral DNA, modified by the tumor tissue, into the plasma. Digital PCR platforms such as the one behind NavDx amplify and count these target sequences, producing a quantitative measure of circulating tumor burden. Unlike imaging, which depends on anatomical changes large enough to be visually resolved, the molecular assay can in principle register subclinical disease before structural changes appear on scans. The study’s finding that ctHPVDNA detected distant recurrences as well as locoregional ones is particularly notable, since distant metastases in the lungs or elsewhere are often the hardest events for routine neck imaging to catch early.

The clinical implications extend beyond diagnostic statistics. False-positive imaging findings in this study triggered additional workup and, in some cases, raised the specter of unwarranted salvage operations, procedures that carry real morbidity, heighten patient anxiety, and add substantial financial toxicity. The authors argue that a surveillance strategy anchored in ctHPVDNA could reduce the need for repeat imaging and prevent unnecessary interventions, reserving invasive procedures for patients whose molecular signal confirms genuine disease. Conversely, the high negative predictive value suggests that a clear blood test could offer patients and clinicians greater confidence that no recurrence is present, potentially streamlining follow-up schedules that currently rely on serial scanning.

Important caveats temper these results. The study was a single-institution retrospective review with only sixteen patients and four recurrence events, a level of evidence the authors themselves classify as level 4. Perfect sensitivity and specificity in such a small sample will almost certainly narrow in larger, prospective validations, and the assay’s performance in patients treated primarily with radiation rather than surgery remains to be established in this dataset. Questions also persist about optimal testing frequency, the quantitative thresholds that best distinguish clinically meaningful disease from transient signal, and how ctHPVDNA results should be integrated with imaging rather than simply replacing it, since anatomical localization remains essential for planning any salvage treatment.

Nevertheless, the findings add to a growing body of evidence that molecular surveillance of HPV-associated cancers can outperform anatomical imaging, echoing the way prostate-specific antigen transformed monitoring of prostate cancer decades ago. For a cancer population that is young, often curatively treated, and destined to live for decades under surveillance, the prospect of a blood test that reliably rules recurrence in or out carries enormous weight, both medically and psychologically. Larger prospective studies will determine whether ctHPVDNA surveillance can move from promising retrospective data to standard practice, but this early signal from surgical patients suggests that the era of watching for returning throat cancer with blood rather than scanners may be drawing closer.

Subject of Research: Circulating tumor HPV DNA surveillance for recurrence detection in surgically treated HPV-positive oropharyngeal squamous cell carcinoma

Article Title: NavDx (ctHPVDNA) recurrence detection in surgically treated human papillomavirus-associated oropharyngeal squamous cell carcinoma

Article References: Matthews, M. R., Van Dorsten, A. L., Heetderks, K. A., Yarbrough, W. G., Oldan, J. D., Huang, B. Y., Shen, C., & Hackman, T. G. (2026). NavDx (ctHPVDNA) recurrence detection in surgically treated human papillomavirus-associated oropharyngeal squamous cell carcinoma. BMC Cancer. https://doi.org/10.1186/s12885-026-17011-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17011-0

Keywords: HPV-positive oropharyngeal cancer, circulating tumor HPV DNA, liquid biopsy, NavDx, cancer recurrence surveillance, NI-RADS imaging, head and neck cancer, digital PCR, salvage surgery, tumor tissue modified viral DNA, post-treatment monitoring, BMC Cancer

Oropharyngeal squamous cell carcinoma, which arises in the tonsils and base of the tongue, has become increasingly common in developed countries, driven largely by HPV infection. Tumours linked to the virus respond unusually well to treatment, and patients with HPV-positive disease enjoy substantially better survival than those whose cancers are tobacco-related. That favourable biology has fuelled a worldwide effort to de-escalate therapy: if standard treatment cures more than 90 percent of patients, clinicians argue, the intensity of that treatment can perhaps be reduced without compromising outcomes. Radiation, even in modern intensity-modulated form, carries a heavy burden of long-term toxicity, including dry mouth, difficulty swallowing, neck stiffness, hypothyroidism, and, in some patients, the need for long-term feeding tubes.

Previous de-escalation attempts have taken two broad routes. One approach reduces the dose of radiation delivered after biopsy-definitive diagnosis, as tested in trials such as E1308 and OPTIMA, which used induction chemotherapy to select patients for reduced-dose chemoradiation. Another strategy replaces radiation with transoral surgery, exemplified by the E3311 trial of transoral robotic surgery with risk-based adjuvant therapy and the ORATOR randomised comparison of surgery versus radiotherapy. The Japanese trial takes a distinctive third path: it uses chemotherapy first to shrink the tumour, then performs less invasive transoral surgery, and withholds all postoperative radiation when pathology shows the disease has been eradicated.

In the trial, 32 eligible patients with HPV-associated resectable oropharyngeal cancer received three cycles of NAC-TPF before undergoing surgery. Thirty patients successfully underwent transoral surgery after the chemotherapy, and an R0 resection, meaning complete removal of the tumour with clear microscopic margins, was confirmed in 31 patients. The primary endpoint was the centrally reviewed pathological complete response rate, in which pathologists examine the surgical specimen and find no residual viable cancer. The pCR rate reached 65.6 percent, and a virological complete response, in which no high-risk HPV RNA could be detected in tumour specimens from either the primary site or the lymph nodes, was achieved in 64.5 percent of patients.

Although the trial formally missed its prespecified primary endpoint, the investigators concluded that the response rate was clinically meaningful and, more importantly, that the treatment sequence allowed 91 percent of patients to avoid postoperative radiotherapy or postoperative chemoradiotherapy entirely. For those patients, the entire course of cancer care consisted of chemotherapy followed by surgery, sparing them the swallowing dysfunction, xerostomia, and fibrosis that radiation to the throat typically causes. The trial was registered as jRCT1041220029 and was supported by the Japan Agency for Medical Research and Development, with participation from more than a dozen Japanese institutions including Shizuoka Cancer Center, National Cancer Center Hospital, and several university hospitals.

The study went beyond pathology to track molecular and patient-reported outcomes. Researchers measured levels of high-risk HPV RNA in tumour specimens and circulating tumour HPV DNA in blood plasma, an emerging biomarker that reflects fragments of DNA shed by tumour cells into the bloodstream. After neoadjuvant chemotherapy, 23 patients showed undetectable levels of circulating tumour HPV DNA, suggesting that the molecular footprint of the cancer had been eliminated in most participants. Liquid biopsy monitoring of this kind is increasingly viewed as a promising tool for identifying which patients can safely forgo intensive adjuvant therapy and for detecting recurrence earlier than imaging alone.

Quality of life was assessed prospectively using validated instruments, including the 30-item European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. All measured quality-of-life scores returned to baseline values or improved within one year of treatment. This finding stands in sharp contrast to the trajectory often seen after chemoradiotherapy for head and neck cancer, where studies have documented persistent declines in swallowing, dry mouth, and social functioning years after treatment completion. For a disease that disproportionately affects middle-aged adults, the ability to return to baseline function within a year represents a substantial practical benefit.

The biological rationale for the approach rests on the chemosensitivity of HPV-positive tumours. Viral oncogene-driven cancers undergo apoptosis more readily when exposed to DNA-damaging agents, and prior pathological studies of p16-positive oropharyngeal carcinoma have shown deep tumour regression after neoadjuvant chemotherapy. By administering chemotherapy before any local therapy, clinicians can also gauge response directly: the surgical specimen provides definitive pathological evidence of how completely the tumour was eradicated. Patients whose specimens show residual disease can still receive postoperative radiation or chemoradiotherapy as salvage, which is precisely why the trial design preserved standard adjuvant treatment for the minority who needed it.

The trial’s limitations are those inherent to a single-arm Phase II study of modest size. Without a randomised control group, the durability of disease control and survival cannot be established, and longer follow-up will be required to confirm that avoiding radiation does not compromise cure rates in the 91 percent of patients who skipped it. The primary endpoint threshold was not met, meaning the results cannot by themselves change practice guidelines. Nevertheless, the investigators argue that the combination of a 65.6 percent pathological complete response rate, near-universal R0 resection, molecular clearance of circulating tumour HPV DNA in most patients, and full quality-of-life recovery constitutes a compelling signal that deserves testing in larger, ideally randomised, Phase III studies.

The findings arrive amid a rapidly evolving landscape of de-escalation research. Recent trials have explored neoadjuvant immunotherapy combined with chemotherapy before transoral surgery, including studies of nivolumab and sintilimab, and long-term follow-up of E3311 has continued to support risk-based adjuvant treatment decisions after robotic surgery. The Japanese trial adds an important data point: chemotherapy-first sequencing can convert a substantial fraction of HPV-associated oropharyngeal cancers into surgically curable disease without any radiation exposure. If ongoing and future studies confirm these results, the standard of care for HPV-positive throat cancer could shift decisively away from radiotherapy-based regimens toward response-adapted strategies in which the intensity of treatment is tailored to how completely each patient’s tumour responds to initial systemic therapy.

Subject of Research: Neoadjuvant triplet chemotherapy as a radiotherapy-sparing strategy for HPV-associated oropharyngeal squamous cell carcinoma

Article Title: Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial

Article References: Yokota, T., Tsuzuki, T., Onitsuka, T., Iizuka, A., Ouchi, Y., Mori, T., Tsukahara, K., Hanyu, K., Mukaigawa, T., Nakashima, T., Uryu, H., Omura, G., Nakamura, H., Uemura, H., Nishikawa, D., Kano, S., Akiyama, Y., Onoe, T., Oyamada, S., & Yamaguchi, T. (2026). Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03610-y

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03610-y

Keywords: HPV-associated oropharyngeal cancer, neoadjuvant chemotherapy, NAC-TPF, transoral surgery, radiotherapy de-escalation, pathological complete response, circulating tumor HPV DNA, Phase II trial, quality of life, head and neck cancer, British Journal of Cancer, treatment de-escalation